<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s8{border-left: none;background-color:#ffffff;}.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{border-left: none;border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{background-color:#ffffff;text-align:left;font-style:italic;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s9{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'docs-Roboto',Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-left: none;border-right: none;background-color:#ffffff;}.ritz .waffle .s10{background-color:#ffffff;text-align:left;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{border-right: none;background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1610528278C0" style="width:100px;" class="column-headers-background">A</th><th id="1610528278C1" style="width:100px;" class="column-headers-background">B</th><th id="1610528278C2" style="width:100px;" class="column-headers-background">C</th></tr></thead><tbody><tr style="height: 20px"><th id="1610528278R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">GTD</td><td class="s1" dir="ltr">Source</td><td class="s1" dir="ltr">GTG 38</td></tr><tr style="height: 20px"><th id="1610528278R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2" dir="ltr">Types</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1098px;left:-1px">Complete molar pregnancy - empty egg fertilised by sperm (single sperm in 80-90% of cases, 46XX in most cases, 5-10% have a Y-chromosome consistent with dispermic ensemination)</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1298px;left:-1px">Partial molar pregnancy - normal egg fertilised by either one or two sperm - mostly from single sperm then duplication of parental genetics to produce 69 XXX or 69 XXY karyotype, XYY rarely seen, YYY never seen</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">Gestational Trophoblastic Neoplasia (GTN) - occurs in approx 15–20% of patients after evac of complete mole and up to 8% after partial mole</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s1" dir="ltr"></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s6" dir="ltr">GTN subtypes</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">Invasive moles (chorioadenoma destruens): Cancerous growths that can develop from molar pregnancies but rarely spread outside of the uterus.</div></td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr"></td></tr><tr style="height: 20px"><th id="1610528278R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">Choriocarcinoma: <br>1:30,000 pregnancies, half after term pregnancies, 25% after molar pregnancies, remainder from others (ectopics / miscarriages)<br>Most aggressive form of GTN and can spread throughout the pelvis and to distant sites, such as the lungs, brain, liver, and kidneys.</div></td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr"></td></tr><tr style="height: 20px"><th id="1610528278R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">Placental-site trophoblastic tumor (PSTT): A very rare, slow-growing cancer that develops from the placenta.</div></td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr"></td></tr><tr style="height: 20px"><th id="1610528278R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">Epithelioid trophoblastic tumor (ETT): A very rare cancer that is similar to choriocarcinoma but less aggressive.</div></td><td class="s7" dir="ltr"></td><td class="s7" dir="ltr"></td></tr><tr style="height: 20px"><th id="1610528278R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s1" dir="ltr"></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s2" dir="ltr">Presentation</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">The classic features of molar pregnancy are irregular vaginal bleeding, hyperemesis, excessive uterine enlargement and early failed pregnancy</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">Other features are passing of hydropic villa per vaginum, theca lutein cysts and early-onset pregnancy induced hypertension</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s2" dir="ltr">Diagnosis</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">USS suggestive, histology definitive</div></td><td class="s4"></td><td class="s8"></td></tr><tr style="height: 20px"><th id="1610528278R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s2" dir="ltr">Management</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s9" dir="ltr">Molar pregnancy</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Advise suction curettage - if partial molar fetal parts too large - advise medical evacuation.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">Avoid use of oxytocin during surgery due to the risk of disseminating the disease - only consider during haemorrhage at theatre.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">If repeat evacuation required, consult with regional centre.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:698px;left:-1px">All patients with any type of GTD need registration with regional centre and written info regarding their condition.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s10" dir="ltr">GTN</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Women with GTN may be treated either with single-agent or multi-agent chemotherapy for GTN. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">The need for chemotherapy following a complete mole is 15% and 0.5 % after a partial mole. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">The development of postpartum GTN requiring chemotherapy occurs at a rate of 1/50 000 births.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Women are assessed before chemotherapy using the FIGO 2000 scoring system</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:998px;left:-1px">Women with scores ≤ 6 are at low risk and are treated with single-agent intramuscular methotrexate alternating daily with folinic acid for 1 week followed by 6 rest days. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:1298px;left:-1px">Women with scores ≥ 7 are at high risk and are treated with intravenous multi-agent chemotherapy, which includes combinations of methotrexate, dactinomycin, etoposide, cyclophosphamide and vincristine. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:798px;left:-1px">Treatment is continued, in all cases, until the hCG level has returned to normal and then for a further 6 consecutive weeks. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">The cure rate for women with a score ≤ 6 is almost 100%; the rate for women with a score ≥ 7 is 95%.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">Following chemotherapy, avoid pregnancy for at least 1 year.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s2" dir="ltr">Follow up</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">If hCG has reverted to normal within 56 days of the pregnancy event then follow up will be for 6 months from the date of uterine evacuation. </div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R40" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">41</div></th><td class="s5 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">If hCG has not reverted to normal within 56 days of the pregnancy event then follow-up will be for 6 months from normalisation of the hCG level.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R41" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">42</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:898px;left:-1px">Notify regional centre of outcome of any subsequent pregnancy including live birth and measure bHCG 6-8 weeks post subsequent pregnancy.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R42" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">43</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R43" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">44</div></th><td class="s2" dir="ltr">Contraception</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R44" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">45</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:298px;left:-1px">Advise barrier methods until bHCG normal.</div></td><td class="s4"></td><td class="s8"></td></tr><tr style="height: 20px"><th id="1610528278R45" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">46</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:198px;left:-1px">Offer COCP after bHCG normal.</div></td><td class="s8"></td><td class="s8"></td></tr><tr style="height: 20px"><th id="1610528278R46" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">47</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:598px;left:-1px">Advise if started oral contraception prior to bHCG normalisation, can continue but risk is of GTN.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R47" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">48</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Advise against IUD particularly until bHCG normal as risk of perforation.</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R48" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">49</div></th><td></td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R49" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">50</div></th><td class="s2" dir="ltr">Prognosis</td><td></td><td></td></tr><tr style="height: 20px"><th id="1610528278R50" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">51</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:398px;left:-1px">high cure (98–100%) and low (5–8%) chemotherapy rates</div></td><td class="s4"></td><td class="s4"></td></tr><tr style="height: 20px"><th id="1610528278R51" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">52</div></th><td class="s3 softmerge" dir="ltr"><div class="softmerge-inner" style="width:498px;left:-1px">Earlier menopause (by 1 year) for patients that required chemotherapy</div></td><td class="s4"></td><td class="s4"></td></tr></tbody></table></div>